Jacobio divests cardiovascular program to sharpen oncology focus

Jacobio Pharmaceuticals Group Co., Ltd. has divested an 80% equity interest in Jacoray, its early-stage cardiovascular research and development project company. This was done through a Capital Increase Agreement and an Equity Transfer Agreement. Beijing Jacobio, Jacoray, and an Industry Partner finalized the Capital Increase Agreement. Beijing Jacobio, Jacoray, Oceanpine Capital, and the Industry Partner then entered into the Equity Transfer Agreement.

Oceanpine Capital will pay Beijing Jacobio RMB125 million upfront, with an additional RMB75 million milestone payment, to acquire its 80% stake in Jacoray. Following these transactions, Jacoray’s ownership will be 10% for Beijing Jacobio, 80% for Oceanpine Capital, and 10% for the Industry Partner. The proceeds are earmarked for the research, development, production, and commercialization of Jacobio’s Pan-KRAS inhibitor and other oncology therapies.

This move aligns with Jacobio’s strategic objective to concentrate on core oncology pipeline products, including KRAS, MYC, P53, and tumor immunity. The company aims to optimize capital allocation and enhance organizational efficiency while retaining future value through a risk-sharing model.